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Background: Ouabain (OUA) is a newly recognized hormone that is synthesized in the adrenal cortex and
hypothalamus. Low doses of OUA can activate a signaling pathway by interaction with Na,K-ATPase, which is
protective against a number of insults. OUA has central and peripheral anti-inflammatory effects. Lipopolysaccharide
(LPS), via toll-like receptor 4 activation, is a widely used model to induce systemic inflammation. This study used a
low OUA dose to evaluate its effects on inflammation induced by LPS injection in rats.
Methods: Adult male Wistar rats received acute intraperitoneal (ip) OUA (1.8 μg/kg) or saline 20 minutes before LPS
(200 μg/kg, ip) or saline injection. Some of the animals had their femoral artery catheterized in order to assess
arterial blood pressure values before and after OUA administration. Na,K-ATPase activity, cytokine mRNA levels,
apoptosis-related proteins, NF-κB activation brain-derived neurotrophic factor BDNF, corticosterone and TNF-α levels
were measured.
Results: OUA pretreatment decreased mRNA levels of the pro-inflammatory cytokines, inducible nitric oxide
synthase (iNOS) and IL-1β, which are activated by LPS in the hippocampus, but with no effect on serum measures of
these factors. None of these OUA effects were linked to Na,K-ATPase activity. The involvement of the inflammatory
transcription factor NF-κB in the OUA effect was indicated by its prevention of LPS-induced nuclear translocation of the
NF-κB subunit, RELA (p65), as well as the decreased cytosol levels of the NF-κB inhibitor, IKB, in the hippocampus. OUA
pretreatment reversed the LPS-induced glial fibrillary acidic protein (GFAP) activation and associated inflammation in
the dentate gyrus. OUA also prevented LPS-induced increases in the hippocampal Bax/Bcl2 ratio suggesting an
anti-apoptotic action in the brain.
Conclusion: Our results suggest that a low dose of OUA has an important anti-inflammatory effect in the rat
hippocampus. This effect was associated with decreased GFAP induction by LPS in the dentate gyrus, a brain area
linked to adult neurogenesis.
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Na,K-ATPase (NKA) is a membrane protein that is
essential for the survival of the organism. This enzyme is
expressed in all the cells of the human body, having
many functions including the maintenance of osmotic
balance, cell volume, pH and membrane potential. This
occurs by the hydrolysis of an adenosine triphosphate
(ATP) molecule leading to the export of three sodium
ions and the import of two potassium ions into the
cell, which is fundamental for neuronal excitability
and cell maintenance [1,2].
NKA is constituted of three subunits: α, β and γ [3],
with each subunit having a number of isoforms that
provide functional versatility across different cell types, in
turn highlighting the different roles and responses
produced by NKA activation across cell types [4-8].
However, the γ (gamma) subunit, is not present in all
the cells, with the other subunits being required for
NKA to be functional [9].
In the adult brain, α1 is expressed in all cells, with α2
being expressed primarily in astrocytes and α3 in
neurons [10,11]. Mutations in the α2- and α3-isoform
genes are involved in neurological disorders, such as
familial hemiplegic migraine type-2 [12], rapid-onset
dystonia [13], alternating hemiplegia of childhood
[14] and cerebellar ataxia, areflexia, pes cavus, optic
atrophy and sensorineural hearing loss (CAPOS) [15],
with genetic variations in NKA also associating with
bipolar disorder, suggesting a role for this enzyme in
the etiology of this disease [16]. The NKA α-isoform
plays a critical role in the modulation of learning and
memory, in turn regulating susceptibility to Alzheimer’s
disease [17]. Several works show NKA to operate as a
receptor and not only as a pump, with a number of
intracellular pathway activations driving its effects [18,19].
Ouabain (OUA) is synthesized by the adrenal gland
and hypothalamus [20,21] and is likely to have important
physiological roles in both the central and peripheral
nervous systems [22,23]. OUA binds to NKA in hippocam-
pal astrocytes, activating inositol trisphosphate receptor
(InsP3R), which generates calcium oscillations, thereby acti-
vating NF-κB [23]. Xie and Askari [24] also showed OUA
to act as a signal transducer, by binding to NKA and
thereby activating the Ras-Raf-MAPK signaling cascade by
the epidermal growth factor receptor (EGFR).
OUA has a dual role, given its dose-dependent response
curve effects. A high concentration of OUA can cause cell
death, driving neuronal necrosis via NKA inhibition,
leading to potassium ion depletion and thereby increasing
intracellular sodium and calcium ions [25]. Conversely,
low concentrations of OUA (0.01 nM) are protective
against kainic acid-induced lesions in the rat striatum,
where it reduces apoptosis by increasing Bcl-2 [26].
Similarly, OUA affords protection in rat kidney primarycultures against Shiga toxin [27]. As such, OUA can afford
protection both peripherally and centrally.
NF-κB is a nuclear transcription factor, which is
commonly induced following danger or inflammatory
signaling, including by lipopolysaccharide (LPS) [28].
NF-κB comprises homo- and heterodimers via the
combination of the subunits p65 (RELA), p50, p52, c-REL
and REL of the REL/NF-κB family of proteins [28].
Different dimer combinations can activate or block
distinct gene transcriptions, exemplified by the inhibitory
homodimers p50/p50 and p52/p52 [29]. This transcription
factor is evolutionarily conserved, driving a wide range of
effects that depend on the specific activating stimulus,
particular cell type and the cellular phenomenon that it
regulates.
When it is not stimulated, NF-κB resides in the cytoplasm
in association with the inhibitory protein, IκB (IKB) [30].
When IKB is phosphorylated by IKK (IκB kinase), IKB is
degraded by proteasome 26S [31], freeing NF-κB, which can
then translocate to the nucleus and bind to the regulatory
sequence close to the promotor region, thereby regulating
the expression of target genes such as, the pro-apoptotic
Bax, anti-apoptotic Bcl2, inducible nitric oxide synthase
(iNOS), several cytokines, manganese-superoxide dismutase
(MnSOD) and brain-derived neurotrophic factor (BDNF)
[29]. BDNF is an important trophic protein, including in the
central nervous system (CNS), where it plays important
roles in brain development and plasticity, with its malfunc-
tion being involved in many CNS diseases [32]. In the CNS,
NF-κB plays a dual role in neurodegenerative diseases,
enhancing survival in neurons, whilst driving pathological
glial inflammatory processes [33].
LPS is a bacterial Gram-negative membrane element
which is released in a free form or in aggregates. LPS is
classically utilized as a model of inflammation and sepsis,
with effects via toll-like receptor 4 (TLR4) [34,35].
Peripheral LPS administration induces NF-κB activation
in different brain areas [36], as well as de novo synthesis of
Iκb mRNA (an NF-κB activation index), in the brain
parenchyma [37]. Peripheral LPS can, therefore, activate
pro-inflammatory CNS genes [38]. The present work aims
to evaluate the alterations induced by a low dose of OUA
in the rat hippocampus, in an inflammation model
induced by intraperitoneal (ip) LPS injection.
Methods
Animal and tissue preparation
Three-month old male Wistar rats (Biomedical Sciences
Institute, University of São Paulo) were kept under
12 hour light/dark cycle (lights on at 7:00 am) and
allowed free access to food and water. Animals were
treated with OUA (1.8 μg/kg, ip) or saline 20 minutes
before the injection LPS (200 μg/kg, ip) or saline and
euthanized 2 hours after the administration (between
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the Biomedical College of Animal Experimentation
(COBEA). All procedures were also approved by the
Ethical Committee for Animal Research (CEEA) of the
Biomedical Sciences Institute of the University of São
Paulo. The brain was immediately removed and immersed
in cold PBS. Each hippocampus was rapidly dissected,
quickly immersed in liquid nitrogen, and stored at −80°C
for later use.
Hemodynamic parameters
Male Wistar rats (n = 4) were anesthetized with a
ketamine, xylazine and acepromazine mixture (64.9,
3.2 and 0.78 mg/kg). The left femoral artery was cannulated
with a polyethylene catheter (PE-10 connected to PE-50
filled with heparinized saline, (BD,New Jersey, NY, USA)
that was exteriorized in the mid-scapular region. After
24 hours, arterial pressure and heart rate were measured in
conscious animals by a pressure transducer (model
DT-100, Utah Medical Products, Midvale, UT, USA) and
recorded using an interface and software for computer
data acquisition (Power Lab 4/25, AD Instruments,
Sidney, Australia). Heart rate was determined from the
intra-beat intervals. The effects of OUA (1.8 μg/kg, ip) on
the arterial blood pressure and heart rate, was evaluated
before and 1 hour after OUA administration in conscious
animals. Results are expressed as mean ± SE.
Chemicals and kits
Routine reagents, OUA and LPS from Escherichia coli
O111:B4 were purchased from Sigma Chemicals (St. Louis,
MO, USA); Bio-Rad protein assay kit was purchased from
Bio-Rad (Hercules, CA, USA). Corticosterone, TNF-α and
BDNF immunoassay kits were purchased from Enzo Life
Sciences, Inc. (Farmingdale, NY, USA), eBioscience
(San Diego, CA, USA) and Promega (Fitchburg, WI,
USA), respectively. The kits were utilized according to
manufacturer instructions. All solutions were prepared
immediately before use.
Semiquantitative RT-PCR determination of inducible nitric
oxide synthase (iNos), Il-1β, Bax and Bcl2 mRNA levels
The effect of OUA on LPS-modulated gene expression
in the hippocampus of rats was measured. Total RNA
was isolated with Trizol reagent (Invitrogen, Carlsbad,
CA, USA) from the hippocampus according to the
manufacturer's instructions. Semiquantitative reverse
transcription-PCR (RT-PCR) amplification was performed
using the ThermoScript RT kit (Invitrogen, Carlsbad, CA,
USA) according to the manufacturer's instructions. The
primer sequences were: iNos (GenBank access number
012611.3, 651 bp) 5′-GTGCTAATGCGGAAGGTCATA-3′
(sense) and 5′CCAAATGTGCTTGTCACCACA-3′ (anti-
sense); Bax (GenBank access number 017059.1, 260 bp),5′-TGAACTGGACAACAACATGGAGC-3′ (sense) and
5′-GGTCTTGGATCCAGACAAACAGC-3′ (antisense);
Bcl2 (GenBank access number 016993.1, 271 bp), 5-′
GGAGGATTGTGGCCTTCTTTGAG-3′ (sense) and 5′-
TATGCACCCAGAGTGATGCAGGC-3′(antisense); Il-
1β (GenBank access number 031512.2, 1,339 bp), 5′-
ATGCTCAGCAGTCAAGTGCC-3′ (sense) and 5′-
AGCCTT CCTTCGTGTAACCC-3′ (antisense).
The PCR conditions consisted of 5 minutes at 94°C,
33 cycles of 94°C for 45 seconds, 63 °C for 45 seconds, and
72°C for 1 minute and 30 seconds and a final extension at
72°C for 10 minutes. Glyceraldehyde-3-phosphate dehydro-
genase (Gapdh; GenBank access number 017008.3, 264 bp)
was also amplified as an internal PCR control using the fol-
lowing primers: 5′-CGGGAAGCTTGTGATCAATGG-3′
(sense) and 5′-GGCAGTGATGCCATGGACTG-3′ (anti-
sense). In this case, the temperature cycling conditions were
as follows: 5 minutes at 94°C, 20 cycles of 94°C for
45 seconds, 63°C for 45 seconds, and 72°C for 1 minute
and 30 seconds and a final extension at 72°C for 10 minutes.
Gel electrophoresis of the PCR product was performed
using an ethidium bromide-containing agarose gel (2%),
and resulting bands were visualized under UV light.
The photographs were captured by photo documentation
system DP-001-FDC (VilberLourmat, Torcy, France), and
the optical density of the bands was determined using
NIH ImageJ software (http://rsb.info.nih.gov/ij). Results
were expressed in relation to the intensity of Gapdh
mRNA levels.
Protein extraction
Nuclear extract of each hippocampus was prepared as
previously described [39]. Briefly, hippocampal struc-
tures were homogenized using a Dounce homogenizer
in cold PBS supplemented with 0.5 mM dithiothreitol
(DTT), 0.5 mM phenylmethylsulfonide fluoride (PMSF),
2 μg/ml leupeptin, 2 μg/ml antipain, and 3 mM sodium
orthovanadate and centrifuged at 4°C for 30 seconds at
12,000 g. Supernatant was discarded and pellet was
resuspended in lysis buffer (10 mM HEPES, pH 7.9,
1.5 mM MgCl2, 10 mM KCl, 0.1 mM ethylenediamine-
tetraacetic acid (EDTA), 0.5 mM DTT, 0.5 mM PMSF,
2 μg/ml leupeptin, 2 μg/ml antipain, and 3 mM sodium
orthovanadate) and incubated on ice for 10 minutes.
After addition of NP-40 (10%), samples were vigorously
mixed and centrifuged for 30 seconds at 12,000 g. The
supernatant was reserved for Western blotting and
enzymatic assays (cytosolic fraction), and the pellet was
resuspended in lysis buffer (10 mM HEPES, pH 7.9,
1.5 mM MgCl2, 10 mM KCl, 0.1 mM EDTA, 0.5 mM
DTT, 0.5 mM PMSF, 2 μg/ml leupeptin, 2 μg/ml
antipain, and 3 mM sodium orthovanadate) and incubated
on ice for 10 minutes. After addition of NP-40 (10%),
samples were vigorously mixed and centrifuged for
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and the pellet was resuspended in extraction buffer
(20 mM HEPES, pH 7.9, 25% glycerol, 1.5 mM
MgCl2, 300 mM NaCl, 0.25 mM EDTA, 0.5 mM
DTT, 0.5 mM PMSF, 2 lg/ml leupeptin, 2 lg/ml antipain,
and 3 mM sodium orthovanadate), incubated for 20 minutes
on ice, and centrifuged for 20 minutes at 12,000 g at 4°C.
The resulting supernatants containing nuclear proteins
were stored at −80°C and used to test the expression of
RELA. Protein concentration was determined using the
Bio-Rad protein reagent (Hercules, CA, USA).
Western blotting
Electrophoresis was performed using 10% polyacrylamide
gel and the Bio-Rad mini-Protean III apparatus (Bio-Rad,
Hercules, CA, USA). In brief, the proteins present in
the hippocampal cytosolic and nuclear fractions were
size-separated in 10% SDS-PAGE (90 V). The proteins
were blotted onto a nitrocellulose membrane (Bio-Rad,
Hercules, CA, USA) and incubated with the specific anti-
body RELA (p65) (sc-0372; Santa Cruz Biotechnology,
Santa Cruz, CA, USA) and IKB (sc-0371; Santa Cruz Bio-
technology, Santa Cruz, CA, USA). The Ponceau method
to immunoblot was used to ensure equal protein loading
[40]. Proteins recognized by antibodies were revealed by
an electrochemiluminescence (ECL) technique, following
the manufacturer's instructions (Amersham Biosciences,
Amersham, UK). To standardize and quantify the immu-
noblots, we used the photo documentation system
DP-001-FDC (VilberLourmat, Torcy, France) and NIH
ImageJ software (http://rsb.info.nih.gov/ij). Several exposure
times were analyzed to ensure the linearity of the
band intensities. β-ACTIN antibody (sc-1616; Santa
Cruz Biotechnology, Santa Cruz, CA, USA) was used as
an internal experimental control, with results expressed in
relation to β-ACTIN intensity.
Measurement of Na, K-ATPase activity
The NKA activity was determined by assaying Pi
released from ATP hydrolysis. This inorganic compound
forms a complex with molybdate which can be read spec-
trophotometrically at 700 nm [41]. For this colorimetric
ATP assay, hippocampus supernatant (S1) was centrifuged
(12,000 g for 15 minutes at 4°C). The particulate fraction
was resuspended in a buffer containing: 0.32 M sucrose,
20 mM HEPES, 1 mM EDTA, 1 mM DTT, and 1 mM
PMSF, pH 7.4.
Protein content was determined in particulate samples
by colorimetric assay (Bio-Rad, Hercules, CA, USA)
[42]. NKA activity was tested by adding 10 μg of the
particulate fraction (in 40 μl of buffer) to 360 μl of
buffer containing: 3 mM ATP, 120 mM NaCl, 2 mM
KCl, 3 mM MgCl2, and 30 mM histidine (pH 7.2), with or
without OUA (3 μM or 3 mM). After 20 minutes ofincubation at 37°C, NKA activity was measured. The
reaction was terminated by the addition of a quenching
solution (0.6 ml) containing 1 N H2SO4 and 0.5% am-
monium molybdate. Formation of a phosphomolyb-
date complex was determined spectrophotometrically
at 700 nm [43].
The total ATPase, Mg-ATPase, NKA α1- and α2/3-isoform
activities were linearly related up to 20 minutes. In rodents,
the NKA α1-isoform is 1,000 times less sensitive to
the cardiac glycoside than the NKA α2/3isoform measured
from the difference between OUA-untreated and
OUA-treated samples.
The high-affinity α2/3-isoform fraction was calculated
by subtracting the activity obtained with 3 μM OUA from
total-ATPase activity. To determine the low-affinity fraction
(α1 subunit-associated NKA activity), the values obtained in
the presence of 3 μM OUA were subtracted from those
obtained in the presence of 3 mM OUA. The NKA activity
was expressed as nmol/mg protein x minutes.
Immunofluorescence in the hippocampus
The brain was fixed with paraformaldehyde and kept in
30% sucrose for 48 hours. Hippocampal coronal sections
(30 μm) were cut in the microtome and the tissues
collected were kept in 0.1 M PBS. The sections were incu-
bated with 2% normal donkey serum for 2 hours. For
immunofluorescence reactions, the sections were incubated
overnight with primary antibody (glial fibrillary acidic
protein (GFAP), Sigma-Aldrich, St. Louis, MO, USA) and
4',6-diamidino-2-phenylindole; DAPI), followed by 2-hours
incubation with secondary antibody (Alexa fluor 488
donkey anti-rabbit for GFAP). Six slices were placed in each
slide and mounted with a coverslip. The sections were
examined by fluorescence microscopy (Nikon Eclipse 80i
with DXM 1200C digital camera; Nikon, Tokyo, Japan).
Statistical analysis
Results are expressed as mean ± SEM of the indicated
number of experiments. Statistical comparisons for
OUA-induced changes in mRNA levels, protein expression,
ELISA kits and NKA activities were performed by
one-way analysis of variance (ANOVA), followed by the
Newman-Keuls post-test. All analyses were performed
using a Prism 6 software package (GraphPad Software,
San Diego, CA, USA). P-values < 0.05 were considered to
reflect a statistically significant difference.
Results
OUA (1.8 μg/kg) does not induce any effect in blood
pressure and NKA activity
One-hour OUA administration (1.8 μg/kg; ip) did not
change mean arterial pressure (Before: 113 ± 3.16 versus
After OUA: 112 ± 4.71 mmHg; P > 0.05) or heart rate
(Before: 323 ± 21.35 versus After OUA: 331 ± 15.46 bpm;
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ATPase, Mg-ATPase, α1−NKA and α2/3−NKA activities
(Figure 1) in the rat hippocampus, suggesting the absence
of OUA effects on blood pressure and central NKA activity.
Pretreatment with OUA reduced iNos, Il-1β, and the Bax/
Bcl2 ratio mRNA levels activated by LPS
iNos mRNA levels, an important indicator of inflamma-
tion, increased in the LPS group in comparison with the
control group as expected. OUA pretreatment decreased
the LPS induction of iNos mRNA activation, returning
levels to that of controls. OUA alone had no impact on
iNos mRNA level (Figure 2A). Il-1β mRNA also increased
in the LPS-treated group, which OUA pretreatment
attenuated. OUA itself had no impact on Il-1β mRNA
level (Figure 2B).
We also analyzed changes induced by LPS in the
presence or absence of OUA on the ratio between the
pro-apoptotic protein, Bax, and the anti-apoptotic
protein, Bcl2. LPS increased the hippocampal Bax/
Bcl2 ratio, which OUA pretreatment prevented, suggesting
an anti-apoptotic effect of OUA against LPS. Together,
these data suggest that OUA has anti-inflammatory and
anti-apoptotic effects.
Pretreatment with OUA can block LPS-induced NF-κB
translocation
Western blotting assays showed that LPS (ip) administra-
tion increases both nuclear RELA (p65) translocation andFigure 1 Pretreatment of ouabain (OUA) (1.8 μg/kg) in lipopolysaccha
on Na,K-ATPase (NKA) activity. The total NKA activity was tested by addi
obtained 2 hours after OUA (1.8 μg/kg, ip) or saline pretreatment + LPS (20
obtained with 3 μM OUA (it inhibits just these 2 isoforms) from total NKA a
NKA activity was subtracted from the activity obtained with 3 mM OUA (Mg-A
from five individual experiments. One-way ANOVA followed by Newman-Keucytosolic IKB degradation, which could lead to NF-κB ac-
tivation in the rat hippocampus. Although OUA itself did
not change either nuclear p65 translocation or cytosolic
IKB, it did block LPS-induced RELA (p65) and IKB effects
in the rat hippocampus (Figure 3A and B). The inhibition
of LPS-induced NF-κB translocation by OUA likely
underlies the OUA inhibition of LPS-induced iNos, Il-1β
and increased Bax/Bcl-2 ratio.Pretreatment with OUA can reverse the activation of
astrocytes
GFAP immunofluorescence of the dentate gyrus region of
the hippocampus indicated that LPS induced astrocyte
activation, which OUA pretreatment inhibits (Figure 4).
Increased GFAP expression indicates astrocyte activation,
showing that OUA pretreatment not only has an effect
on pro-inflammatory cytokine levels, but also on the acti-
vation of pro-inflammatory cells in the dentate gyrus.
Such data indicate OUA to be neuroprotective, at least in
part by decreasing astrocyte activation.OUA does not reverse LPS-induced increase in serum
corticosterone and TNF-α levels
Our data showed that LPS, but not OUA, increased
serum levels of corticosterone and TNF-α (Figure 5A
and B). In addition, OUA pretreatment was unable to
block LPS-induced increases in serum corticosterone
and TNF-α.ride (LPS) (200 μg/kg) inflammation model induced no changes
ng 10 μg of the particulate fraction from the rat hippocampus
0 μg/kg, ip). α2/3-NKA activity was measured by subtracting the activity
ctivity. To determine the α1 subunit-associated NKA activity, the total
TPase). Results are expressed as nmol/mg.min protein (mean + SEM)
ls post-test.
Figure 2 Effects of pretreatment of ouabain (OUA) (1.8 μg/kg) in the lipopolysaccharide (LPS) (200 μg/kg) inflammation model on the
mRNA levels of Il-1β, iNos, Bax, and Bcl2. Pretreatment of OUA can decrease the mRNA levels of pro-inflammatory cytokines and pro-apoptotic
proteins. Representative semiquantitative RT- PCR photographs and densitometric analysis (arbitrary units, AU) of the specific bands. mRNA levels
are presented as ratios of the target gene to Gapdh expression. Data are presented as mean ± SEM from five individual experiments. One-way
ANOVA followed by Newman-Keuls post-test. (A) Il-1β mRNA,*P < 0.05 versus control and OUA and **P < 0.01 versus control and OUA and
OUA + LPS. (B) iNos mRNA, *P < 0.05 versus control and OUA + LPS. (C) Bax/Bcl2 ratio,**P < 0.001 versus OUA, control and OUA + LPS and
*P < 0.05 versus OUA.
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OUA or LPS alone significantly decreased BDNF in
comparison to controls, although the decrease induced
by LPS was significantly greater. However, OUA pre-
treatment reversed LPS effects, leading to BDNF
levels at that of controls (Figure 6A). Likewise, LPSor OUA treatment alone increased the inflammatory
cytokine, TNF-α, with OUA pretreatment preventing
LPS-induced TNF-α increases versus control (Figure 6B).
This suggests protection of the rat hippocampus by
OUA pretreatment against the effects of LPS, given that
TNF-α is an important early pro-inflammatory cytokine,
Figure 3 Effects of pretreatment of ouabain (OUA) (1.8 μg/kg) on lipopolysaccharide (LPS)-induced (200 μg/kg) p65 (RELA) subunit
NF-κB nuclear translocation and IκB (IKB) degradation. Pretreatment of OUA blocks the LPS-induced NF-κB activation. (A) Representative
Western blotting autoradiographs and densitometric analysis (arbitrary units, AU) of p65 nuclear/β-ACTIN ratio, *P < 0.05 versus control and OUA + LPS.
(B) Representative Western blotting autoradiographs and densitometric analysis (arbitrary units, AU) of IKB cytosolic/β-ACTIN ratio, *P < 0.05 versus
control, OUA, OUA+ LPS. Data are presented as mean ± SEM from five individual experiments. One-way ANOVA followed by Newman-Keuls post-test.
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being a growth factor.
Discussion
Neuroinflammation can be associated with neurological
insults and neurodegenerative disorders. Neuroinflamma-
tion is characterized by increased pro-inflammatory
cytokines, such as TNF-α and the expression on endothelial
cells of adhesion molecules that increase leukocyte
infiltration over the blood–brain barrier (BBB). Concurrently,
astrocytes and microglia are activated [43].
LPS is an inflammation model that can activate
NF-κB, partly mediated by glutamate acting at N-methyl-
D-aspartate (NMDA) receptors, in turn increasing calcium-
dependent activation of NOS and reactive oxygen species
generation; the latter contributing to membrane peroxida-
tion [36]. NF-κB activation induces the expression of many
inflammatory cytokines and inflammatory factors that drive
the innate immune response [29,44].
However, it is unpredictable as to whether circulating
high concentrations of LPS increase BBB permeability,
leading to the entry of LPS and other molecules into the
brain parenchyma [36,37]. In the early stages of LPS
infection, central areas not protected by the BBB are
likely to contribute to the inflammatory process, including
the actions of LPS at TLR4 in the pineal gland, which
inhibits pineal melatonin production, in turn contributingto increased BBB permeability and immune system
responsivity (reviewed in [45]).
TLR4 is also constitutively expressed in the leptomenin-
ges, choroid plexus, subfornical organ, organum vasculo-
sum of the lamina terminalis, median eminence, and area
postrema. LPS effects in these non-BBB protected areas are
likely to influence the inflammatory response in BBB
protected areas, such as the hippocampus [46]. As such,
LPS inflammatory effects may not be dependent on
increased BBB permeability. The activation of inflammatory
cytokines by LPS in this study confirms the results of previ-
ous studies from our laboratory, which showed that most
of the transcriptional activity regulated by LPS administra-
tion is mediated by the p50/p65 dimer of NF-κB [36,38].
LPS intraperitoneally causes astrocyte activation in the
dentate gyrus in aged rats, with this effect can be prolonged
for many days [47]. Inflammation in the dentate gyrus can
block neurogenesis in adult rats, which can be restored by
an anti-inflammatory drug [48].
It is known that OUA can produce negative effects in
a dose-dependent manner, but many studies have shown
OUA to afford protection centrally and peripherally. In a
serum deprivation model in rat embryonic kidney cell
cultures, OUA prevents cell death by the activation of
NF-κB [49]. It has also been shown that OUA can
protect proximal tubular cells against Shiga toxin by
activating the anti-apoptotic Bcl-xL [27].
Figure 4 The pretreatment of ouabain (OUA) (1.8 μg/kg) on lipopolysaccharide (LPS)-induced (200 μg/kg) astrocyte activation.
Astrocyte activity was measure with glial fibrillary acidic protein (GFAP) immunofluorescence in the dentate gyrus. (A) Representative
photomicrographs showed that LPS increases astrocytic activation, with OUA pretreatment reducing this. The arrow represents an activated astrocyte.
(B) Densitometric analysis of the % of GFAP-positive cells/total cells. *P < 0.05 versus control, OUA and OUA+ LPS. Data are presented as mean ± SEM
from five individual experiments. One-way ANOVA followed by Newman-Keuls post-test.
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humans in the subnanomolar-to-nanomolar concentration
range, non-inhibitory subnanomolar concentration of
OUA might be linked to activation of a signal transducer
pathway in rats since the Km for OUA inhibition of NKA
is 10 to 100 μM for isolated rat vascular smooth muscle,
whilst in humans it is 10 to 100 nM [50,51].
Thus, the OUA concentration (1.8 μg/kg, ip) used in
the present study is likely linked to activation of the
NKA signaling cascade, since in this study we used an
OUA concentration that had no significant impact on
blood pressure and it did not inhibit hippocampal
NKA. As such, the results here are not dependent onFigure 5 Effects of ouabain (OUA) pretreatment (1.8 μg/kg) on lipopolys
TNF-α. (A) The serum levels of corticosterone were elevated in LPS and OUA+
and OUA and bP< 0.01 versus control and OUA. (B) The same pattern occurs i
versus control and OUA. Data are presented as mean ± SEM from five individuaNKA inhibition, but are dependent on changes in
NKA-related signaling. Our data that showed ip LPS ad-
ministration increased the mRNA levels of iNos and Il-1β,
as well as the Bax/Bcl2 ratio, whereas OUA alone had
no impact on the mRNA levels of these factors. However,
we observed a protective effect of OUA, given its decrease
in the mRNA levels of iNos and Il-1β, as well as a decrease
in the Bax/Bcl2 ratio induced by LPS in the hippocampus.
This protection is likely to be afforded by OUA
blocking LPS-induced nuclear translocation of NF-κB
via the RELA (p65) subunit and by decreasing the
degradation of cytosolic IKB, thereby maintaining IKB
linked to NF-κB in the cytosol. The major OUA protectiveaccharide (LPS)-induced (200 μg/kg) serum corticosterone and
LPS in comparison with control and OUA group, aP< 0.01 versus control
n TNF-α serum levels, aP< 0.05 versus control and OUA and bP< 0.05
l experiments. One-way ANOVA followed by Newman-Keuls post-test.
Figure 6 Effects of ouabain (OUA) pretreatment (1.8 μg/kg) on lipopolysaccharide (LPS)-induced (200 μg/kg) regulation of
hippocampal brain-derived neurotrophic factor (BDNF) and TNF-α levels. (A) The levels of BDNF were decreased in LPS and OUA groups in
comparison with control and OUA + LPS group, aP < 0.05 versus control and LPS and bP < 0.01 versus control and OUA + LPS and P < 0.05 versus
OUA. (B) The levels of TNF-α in the hippocampus, aP < 0.01 versus control and OUA + LPS and bP < 0.05 versus control and OUA + LPS. Data are
presented as mean ± SEM from five individual experiments. One-way ANOVA followed by Newman-Keuls test.
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dentate gyrus [52].
Previous studies from our laboratory have reported that
OUA can increase cytokine levels. Such variability in OUA
effects may be due to a number of factors, including testing
times and type of administration, as well as different tissue
and cell models. In fact, we detected changes in cytokines
gene expression 1 hour after injecting OUA directly in to
the CA1 region of the hippocampus at a concentration of
10 nM [53], as well as in in vitro studies (OUA= 10 μM) in
cerebellar primary culture cells [54].
TLR4 decreases neurogenesis and neuronal differenti-
ation, with consequences for neuronal plasticity and
memory [55]. BDNF increases neurogenesis, improves
memory acquisition and has anti-apoptotic and anti-
inflammatory effects, as well as protecting against
hypoxia/ischemia-induced brain injury [56]. OUA pretreat-
ment prevented the decrease in BDNF by LPS, although
OUA alone also decreased BDNF. In fact, we cannot rule
out that BDNF can also be modulated by other transcrip-
tion factors that might be activated by OUA. OUA has both
toxic [57,58] and protective actions against damage to cells
[59,60], including neurons [26]. In the present study, OUA
pretreatment reverted LPS-induced decreases in BDNF
levels, suggesting a specific action of this compound against
the inflammatory signaling response. OUA pretreat-
ment also provided protection against LPS in the rat
hippocampus by decreasing the LPS induction of the
pro-inflammatory cytokine, TNF-α. OUA alone increased
TNF-α, as we found previously [53,54]. This is surprising
as another study showed OUA to block the activation of
the TNF/NF-κB pathway by interfering with the inter-
action between TNF receptor 1 and TRADD in HeLa cell
cultures [61]. Further work should clarify the temporalregulation of TNF-α and/or BDNF by OUA and also its
perhaps differential effects in different cell types. In the
periphery, our data showed that LPS, but not OUA,
increased serum levels of corticosterone and TNF-α,
with OUA pretreatment unable to block these changes.
This could suggest that the OUA concentration used in
the present study may be too low to reverse LPS per-
ipheral activation, although it was high enough to
protect against LPS effects in the hippocampus. This
would imply that OUA protection could be mediated
by its direct action in the brain. Alternatively, the
peripheral effect of LPS may be stronger, with the
OUA concentration used in the current study unable
to reverse the peripheral effects of LPS.
In the peripheral system, mice treated with zymosan and
carrageenan leads to paw edema, with OUA decreasing the
inflammatory response in these models, suggesting that
OUA has peripheral anti-inflammatory effects [62].
However, the OUA concentrations used were higher
than in this current study, with the anti-inflammatory
effects being mediated by different intracellular pathways,
involving the inhibition of prostaglandin E2, bradykinin
and mastocyte degranulation [62]. However, it should be
noted that other mechanisms may be involved in the
anti-inflammatory effects of steroid glycosides, including
decreasing IL-6 [63] and inhibition of genes activated by
TNF-α [64].
Recent studies have shown that low doses of OUA have
anti-inflammatory properties in LPS-treated reactive
astrocytes, by reducing IL-1β release. OUA also prevented
the LPS-induced downregulation of NKA and restored
the actin filaments in reactive astrocytes [65]. This is in
contrast to the effects of OUA in LPS-treated microglia,
where this compound had no effect on levels of microglial
Kinoshita et al. Journal of Neuroinflammation  (2014) 11:218 Page 10 of 12reactivity [66]. This could suggest that some of the
differential effects of OUA on central processing are
determined by the relative levels of microglial and
astrocyte activation, including at different time points
in the inflammatory process.Conclusions
Taken together, the present work showed that OUA pre-
treatment has anti-inflammatory and anti-apoptotic effects
in the hippocampus challenged with LPS-induced
inflammation. This effect is mediated by NF-κB activation,
including in the neurogenesis-associated dentate gyrus.
The ability of OUA to suppress the inflammatory
process and maintain hippocampal BDNF levels in
the face of inflammatory activity suggests that the
NKA signaling cascade could be a new therapeutic target
in neuroinflammation-associated disorders.
Abbreviations
ANOVA: analysis of variance; ATP: adenosine triphosphate; BBB: blood–brain
barrier; BDNF: brain-derived neurotrophic factor; bp: base pair;
CAPOS: cerebellar ataxia, areflexia, pes cavus, optic atrophy and sensorineural
hearing loss; CEEA: Ethical Committee for Animal Research;
COBEA: Biomedical College of Animal Experimentation; CNS: central nervous
system; DAPI: 4',6-diamidino-2-phenylindole; DTT: dithiothreitol;
EDTA: ethylenediaminetetraacetic acid; ECL: electrochemiluminescence;
EGFR: epidermal growth factor receptor; GAPDH: glyceraldehyde-3-
phosphate dehydrogenase; GFAP: glial fibrillary acidic protein; IKB: NF-κB
inhibitor protein; IKK: IκB kinase; IL-1β: interleukin 1 beta; iNOS: inducible
nitric oxide synthase; ip: intraperitoneal; InsP3R: inositol trisphosphate
receptor; Km: Michaelis-Menten equilibrium constant; LPS: lipopolysaccharide;
MnSOD: manganese-superoxide dismutase; NF-κB: nuclear factor kappa B;
NKA: Na,K-ATPase; NMDA: N-methyl-D-aspartate; OUA: ouabain;
PBS: phosphate-buffered saline; PCR: polymerase chain reaction;
PMSF: phenylmethylsulfonide fluoride; TLR4: toll-like receptor 4; TNF-α: tumor
necrosis factor alpha.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
PFK, EMK and CS participated in the research design, data analysis and wrote
or contributed to the writing of the manuscript. All authors read and
approved the final version of the manuscript. PFK performed the
experiments. LMY participated in the data analysis and contributed to
writing the manuscript. ARV, AMMO and LSL participated in the writing of
the manuscript and performed experiments. APDC and LVR participated in
the research design, data analysis and wrote the manuscript section dealing
with blood pressure.
Authors’ information
PFK, ARV and AMMO are supported by a PhD fellowship from Fundação de
Amparo à Pesquisa do Estado de São Paulo (FAPESP), LMY has a
postdoctoral fellowship from FAPESP and LSL is supported by grants from
Universidade de São Paulo. CS, APDC, and LVR are research fellows of
Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq).
Acknowledgements
This publication was made possible by Grants from FAPESP, Conselho
Nacional de Desenvolvimento Científico e Tecnológico (CNPq), the
Neuroscience Research Support Centers (NAPNA), and Center for Research
on Interface Proteolysis-Cell Signaling (NAP) from University of São Paulo. We
thank George Anderson, CRC Scotland & London for English editing.Author details
1Molecular Neuropharmacology Laboratory, Department of Pharmacology,
Institute of Biomedical Science, University of São Paulo, 05508-900 São Paulo,
Brazil. 2Department of Physiology and Biophysics, Institute of Biomedical
Sciences, University of São Paulo, São Paulo, Brazil.
Received: 7 June 2014 Accepted: 8 December 2014References
1. Schoner W: Ouabain, a new steroid hormone of adrenal gland and
hypothalamus. Exp Clin Endocrinol Diabetes 2000, 108:449–454.
2. Kawamura A, Guo J, Itagaki Y, Bell C, Wang Y, Haupert GT Jr, Magil S,
Gallagher RT, Berova N, Nakanishi K: On the structure of endogenous
ouabain. Proc Natl Acad Sci U S A 1999, 96:6654–6659.
3. Albers RW: Cell Membrane Structures and Functions. 6th edition. New York:
Raven Press; 1999.
4. Fambrough DM: The sodium pump becomes a family. Trends Neurosci
1988, 11:325–328.
5. Levenson R: Isoforms of the Na, K-ATPase: family members in search of
function. Rev Physiol Biochem Pharmacol 1994, 123:1–45.
6. Lingrel JB, Kuntzweiler T: Na+, K(+)-ATPase. J Biol Chem 1994,
269:19659–19662.
7. Sweadner KJ: Isozymes of the Na+/K+-ATPase. Biochim Biophys Acta 1989,
988:185–220.
8. Sweadner KJ: Overview: subunit diversity in the Na+/K+-ATPase. Soc Gen
Physiol Ser 1991, 46:63–76.
9. Minor N, Sha Q, Nichols C, Mercer R: The gamma subunit of the Na, K-
ATPase induces cation channel activity. Proc Natl Acad Sci U S A 1998,
95:6521–6525.
10. Beltowski J, Wójcicka G: Regulation of renal tubular sodium transport by
cardiac natriuretic peptides: two decades of research. Med Sci Monit 2002,
8:RA39–RA52.
11. Peng L, Arystarkhova E, Sweadner KJ: Plasticity of Na, K-ATPase isoform
expression in cultures of flat astrocytes: species differences in gene
expression. Glia 1998, 24:257–271.
12. De Fusco M, Marconi R, Silvestri L, Atorino L, Rampoldi L, Morgante L,
Ballabio A, Aridon P, Casari G: Haploinsufficiency of ATP1A2 encoding the
Na+/K+ pump alpha2 subunit associated with familial hemiplegic
migraine type 2. Nat Genet 2003, 33:192–196.
13. Moseley AE, Williams MT, Schaefer TL, Bohanan CS, Neumann JC,
Behbehani MM, Vorhees CV, Lingrel JB: Deficiency in Na, K-ATPase alpha
isoform genes alters spatial learning, motor activity, and anxiety in mice.
J Neurosci 2007, 27:616–626.
14. Heinzen EL, Swoboda KJ, Hitomi Y, Gurrieri F, Nicole S, de Vries B,
Tiziano FD, Fontaine B, Walley NM, Heavin S, Panagiotakaki E, European
Alternating Hemiplegia of Childhood (AHC) Genetics Consortium,
Biobanca e Registro Clinico per l'Emiplegia Alternante (I.B.AHC)
Consortium, European Network for Research on Alternating Hemiplegia
(ENRAH) for Small and Medium-sized Enterpriese (SMEs) Consortium,
Fiori S, Abiusi E, Di Pietro L, Sweney MT, Newcomb TM, Viollet L,
Huff C, Jorde LB, Reyna SP, Murphy KJ, Shianna KV, Gumbs CE,
Little L, Silver K, Ptáček LJ, Haan J, et al: De novo mutations in
ATP1A3 cause alternating hemiplegia of childhood. Nat Genet 2012,
44:1030–1034.
15. Demos MK, van Karnebeek CD, Ross CJ, Adam S, Shen Y, Zhan SH, Shyr C,
Horvath G, Suri M, Fryer A, Jones SJ, Friedman JM, FORGE Canada
Consortium: A novel recurrent mutation in ATP1A3 causes CAPOS
syndrome. Orphanet J Rare Dis 2014, 9:15. doi:10.1186/1750-1172-9-15.
16. Goldstein I, Lerer E, Laiba E, Mallet J, Mujaheed M, Laurent C, Rosen H,
Ebstein RP, Lichtstein D: Association between sodium- and
potassium-activated adenosine triphosphatase alpha isoforms and
bipolar disorders. Biol Psychiatry 2009, 65:985–991.
17. Zhang LN, Sun YJ, Pan S, Li JX, Qu YE, Li Y, Wang YL, Gao ZB: Na(+)-K
(+)-ATPase, a potent neuroprotective modulator against Alzheimer
disease. Fundam Clin Pharmacol 2013, 27:96–103.
18. Aizman O, Aperia A: Na, K-ATPase as a signal transducer. Ann N Y Acad Sci
2003, 986:489–496.
19. Haas M, Wang H, Tian J, Xie Z: Src-mediated inter-receptor cross-talk
between the Na+/K + −ATPase and the epidermal growth factor receptor
Kinoshita et al. Journal of Neuroinflammation  (2014) 11:218 Page 11 of 12relays the signal from ouabain to mitogen-activated protein kinases.
J Biol Chem 2002, 277:18694–18702.
20. Murrell JR, Randall JD, Rosoff J, Zhao JL, Jensen RV, Gullans SR, Haupert GT
Jr: Endogenous ouabain: upregulation of steroidogenic genes in
hypertensive hypothalamus but not adrenal. Circulation 2005,
112:1301–1308.
21. El-Masri MA, Clark BJ, Qazzaz HM, Valdes R Jr: Human adrenal cells in
culture produce both ouabain-like and dihydroouabain-like factors.
Clin Chem 2002, 48:1720–1730.
22. Liu X, Spicarova Z, Rydholm S, Li J, Brismar H, Aperia A: Ankyrin B
modulates the function of Na, K-ATPase/inositol 1,4,5-trisphosphate
receptor signaling microdomain. J Biol Chem 2008, 283:11461–11468.
23. Liu XL, Miyakawa A, Aperia A, Krieger P: Na, K-ATPase generates calcium
oscillations in hippocampal astrocytes. Neuroreport 2007,
18:597–600.
24. Xie Z, Askari A: Na(+)/K(+)-ATPase as a signal transducer. Eur J Biochem
2002, 269:2434–2439.
25. Xiao AY, Wei L, Xia S, Rothman S, Yu SP: Ionic mechanism of
ouabain-induced concurrent apoptosis and necrosis in individual
cultured cortical neurons. J Neurosci 2002, 22:1350–1362.
26. Golden WC, Martin LJ: Low-dose ouabain protects against excitotoxic
apoptosis and up-regulates nuclear BLC-2 in vivo. Neuroscience 2006,
37:133–144.
27. Burlaka I, Liu XL, Rebetz J, Arvidsson I, Yang L, Brismar H, Karpman D,
Aperia A: Ouabain protects against Shiga toxin-triggered apoptosis by
reversing the imbalance between Bax and Bcl-xL. J Am Soc Nephrol 2013,
24:1413–1423.
28. Sen R, Baltimore D: Multiple nuclear factors interact with the
immunoglobulin enhancer sequences. Cell 1986, 46:705–716.
29. Ghosh S, May MJ, Kopp EB: NF-kappa B and Rel proteins: evolutionarily
conserved mediators of immune responses. Annu Rev Immunol 1998,
16:225–260.
30. Baeuerle PA, Baltimore D: NF-kappa B: ten years after. Cell 1996, 87:13–20.
31. Zandi E, Rothwarf DM, Delhase M, Hayakawa M, Karin M: The IkappaB
kinase complex (IKK) contains two kinase subunits, IKKalpha and
IKKbeta, necessary for IkappaB phosphorylation and NF-kappaB
activation. Cell 1997, 91:243–252.
32. Mattson MP: Glutamate and neurotrophic factors in neuronal plasticity
and disease. Ann N Y Acad Sci 2008, 1144:97–112.
33. Camandola S, Mattson MP: NF-kappa B as a therapeutic target in
neurodegenerative diseases. Expert Opin Ther Targets 2007, 11:123–132.
34. Glaros TG, Chang S, Gilliam EA, Maitra U, Deng H, Li L: Causes and
consequences of low grade endotoxemia and inflammatory diseases.
Front Biosci (Schol Ed) 2013, 5:754–765.
35. Kawamoto EM, Scavone C, Mattson MP, Camandola S: Curcumin requires
tumor necrosis factor alpha signaling to alleviate cognitive impairment
elicited by lipopolysaccharide. Neurosignals 2013, 21:75–88.
36. Glezer I, Munhoz CD, Kawamoto EM, Marcourakis T, Avellar MC, Scavone C:
MK-801 and 7-Ni attenuate the activation of brain NF-kappa B induced
by LPS. Neuropharmacology 2003, 45:1120–1129.
37. Laflamme N, Rivest S: Effects of systemic immunogenic insults and
circulating proinflammatory cytokines on the transcription of the
inhibitory factor kappaB alpha within specific cellular populations of the
rat brain. J Neurochem 1999, 73:309–321.
38. Munhoz CD, Lepsch LB, Kawamoto EM, Malta MB, Lima Lde S, Avellar MC,
Sapolsky RM, Scavone C: Chronic unpredictable stress exacerbates
lipopolysaccharide-induced activation of nuclear factor-kappaB in the
frontal cortex and hippocampus via glucocorticoid secretion. J Neurosci
2006, 26:3813–3820.
39. Rong Y, Baudry M: Seizure activity results in a rapid induction of nuclear
factor-kappa B in adult but not juvenile rat limbic structures. J Neurochem.
1996, 67:662–668.
40. Salinovich O, Montelaro R: Reversible staining and peptide mapping of
protein transferred to nitrocellulose after separation by SDS-PAGE.
Anal Biochem 1986, 156:341–347.
41. Esmann M: ATPase and phosphatase activity of Na+, K + −ATPase: molar
and specific activity, protein determination. Methods Enzymol 1988,
156:105–115.
42. Bradford MM: A rapid and sensitive method for the quantitation of
microgram quantities of protein utilizing the principle of protein-dye
binding. Anal Biochem 1976, 72:248–254.43. Gonzales-Scarano F, Baltuch G: Microglia as mediators of inflammatory
and degenerative diseases. Annu Rev Neurosci 1999, 22:219–240.
44. Heese K, Fiebich B, Bauer J, Otten U: NF-kappaB modulates
lipopolysaccharide-induced microglial nerve growth factor expression.
Glia 1998, 22:401–407.
45. Markus RP, Cecon E, Pires-Lapa MA: Immune-pineal axis: nuclear factor κB
(NF-kB) mediates the shift in the melatonin source from pinealocytes to
immune competent cells. Int J Mol Sci 2013, 14:10979–10997.
46. Laflamme N, Soucy G, Rivest S: Circulating cell wall components derived from
Gram-negative, not Gram-positive, bacteria cause a profound induction of
the gene-encoding Toll-like receptor 2 in the CNS. J Neurochem 2001,
79:648–657.
47. Fu H, Yang T, Xiao W, Fan L, Wu Y, Terrando N, Wang T: Prolonged
neuroinflammation after lipopolysaccharide exposure in aged rats. Plos
One 2014, 9:e106331.
48. Monje M, Toda H, Palmer T: Inflammatory blockade restores adult
hippocampal neurogenesis. Science 2003, 302:1760–1765.
49. Li J, Khodus GR, Kruusmagi M, Kamali-Zare P, Liu XL, Eklof AC, Zelenin S,
Brismar H, Aperia A: Ouabain protects against adverse developmental
programming of the kidney. Nat Commun 2010, 1:1–7.
50. Orlov SN, Taurin S, Hamet P: The alpha1-Na/K pump does not mediate
the involvement of ouabain in the development of hypertension in rats.
Blood Press 2002, 11:56–62.
51. Schoner W, Scheiner-Bobis G: Endogenous and exogenous cardiac
glycosides: their roles in hypertension, salt metabolism, and cell growth.
Am J Physiol Cell Physiol 2007, 293:C509–C536.
52. Cameron H, McKay R: Adult neurogenesis produces a large pool of new
granule cells in the dentate gyrus. J Comp Neurol 2001, 435:406–417.
53. Kawamoto EM, Lima LS, Munhoz CD, Yshii LM, Kinoshita PF, Amara FG,
Pestana RR, Orellana AM, Cipolla-Neto J, Britto LR, Avellar MC, Rossoni LV,
Scavone C: Influence of N-methyl-D-aspartate receptors on ouabain
activation of nuclear factor-kappaB in the rat hippocampus. J Neurosci
Res 2012, 90:213–228.
54. de Sa LL, Kawamoto EM, Munhoz CD, Kinoshita PF, Orellana AM, Curi R,
Rossoni LV, Avellar MC, Scavone C: Ouabain activates NFkappaB through
an NMDA signaling pathway in cultured cerebellar cells.
Neuropharmacology 2013, 73:327–336.
55. Rolls A, Shechter R, London A, Ziv Y, Ronen A, Levy R, Schwartz M: Toll-like
receptors modulate adult hippocampal neurogenesis. Nat Cell Biol 2007,
9:1081–1088.
56. Chen A, Xiong L, Tong Y, Mao M: The neuroprotective roles of BDNF in
hypoxic ischemic brain injury. Biomed Rep 2013, 1:167–176.
57. Valente RC, Capella LS, Monteiro RQ, Rumjanek VM, Lopes AG, Capella MA:
Mechanisms of ouabain toxicity. FASEB J 2003, 17:1700–1702.
58. Orlov SN, Thorin-Trescases N, Pchejetski D, Taurin S, Farhat N, Tremblay J,
Thorin E, Hamet P: Na/K pump and endothelial cell survival:
[Na ]i/[K ]i-independent necrosis triggered by ouabain, and
protection against apoptosis mediated by elevation of [Na]i.
Pflugers Arch 2004, 448:335–345.
59. Li J, Zelenin S, Aperia A, Aizman O: Low doses of ouabain protect from serum
deprivation-triggered apoptosis and stimulate kidney cell proliferation via
activation of NF-kappaB. J Am Soc Nephrol 2006, 17:1848–1857.
60. Pasdois P, Quinlan CL, Rissa A, Tariosse L, Vinassa B, Costa AD, Pierre SV,
Dos Santos P, Garlid KD: Ouabain protects rat hearts against
ischemia-reperfusion injury via pathway involving src kinase, mitoKATP,
and ROS. Am J Physiol Heart Circ Physiol 2007, 292:H1470–H1478.
61. Yang Q, Huang W, Jozwik C, Lin Y, Glasman M, Caohuy H, Srivastava M,
Esposito D, Gillette W, Hartley J, Pollard HB: Cardiac glycosides inhibit
TNF-alpha/NF-kappaB signaling by blocking recruitment of TNF
receptor-associated death domain to the TNF receptor. Proc Natl Acad
Sci U S A 2005, 102:9631–9636.
62. de Vasconcelos DI, Leite JA, Carneiro LT, Piuvezam MR, de Lima MR,
de Morais LC, Rumjanek VM, Rodrigues-Mascarenhas S: Anti-inflammatory
and antinociceptive activity of ouabain in mice. Mediators Inflamm 2011,
2011:912925.
63. Matsumori A, Ono K, Nishio R, Igata H, Shioi T, Matsui S, Furukawa Y,
Iwasaki A, Nose Y, Sasayama S: Modulation of cytokine production and
protection against lethal endotoxemia by the cardiac glycoside ouabain.
Circulation 1997, 96:1501–1506.
64. Ye J, Chen S, Maniatis T: Cardiac glycosides are potent inhibitors of
interferon-beta gene expression. Nat Chem Biol 2011, 7:25–33.
Kinoshita et al. Journal of Neuroinflammation  (2014) 11:218 Page 12 of 1265. Forshammar J, Block L, Lundborg C, Biber B, Hansson E: Naloxone and
ouabain in ultralow concentrations restore Na+/K + −ATPase and
cytoskeleton in lipopolysaccharide-treated astrocytes. J Biol Chem 2011,
286:31586–31597.
66. Forshammar J, Jörneberg P, Björklund U, Westerlund A, Lundborg C, Biber B,
Hansson E: Anti-inflammatory substances can influence some glial cell
types but not others. Brain Res 2013, 1539:34–40.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
